{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:13:28Z","timestamp":1783606408376,"version":"3.55.0"},"reference-count":5,"publisher":"Bioscientifica","issue":"Supplement_1","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant endocrine treatment in which therapy is given while the primary tumour is still in the breast provides a highly useful model system by which to identify mechanisms associated with de novo resistance and signs of early acquired resistance. Most importantly, the model is clinically relevant. It has been confirmed that the absence of tumour oestrogen receptors confers resistance to endocrine therapy. Early changes in tumour cell proliferation following neoadjuvant treatment with the third-generation aromatase inhibitor, letrozole, do not predict accurately for subsequent clinical response. Additionally, changes in proliferation seen at later times can be the consequence of response and may be associated with early resistance. High expression of c-erbB2 does not reduce tumour responses to neoadjuvant treatment with aromatase inhibitors, but is associated with high tumour proliferation before and during treatment. It remains to be determined whether these characteristics confer subsequent resistance to treatment and early relapse in the adjuvant setting.<\/jats:p>","DOI":"10.1677\/erc.1.00995","type":"journal-article","created":{"date-parts":[[2005,8,19]],"date-time":"2005-08-19T11:57:55Z","timestamp":1124452675000},"page":"S119-S123","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":6,"title":["Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience"],"prefix":"10.1530","volume":"12","author":[{"given":"W R","family":"Miller","sequence":"first","affiliation":[{"name":"Edinburgh Breast Unit Research Group, Western General Hospital, Edinburgh EH4 2XU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J","family":"Anderson","sequence":"additional","affiliation":[{"name":"Edinburgh Breast Unit Research Group, Western General Hospital, Edinburgh EH4 2XU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"White","sequence":"additional","affiliation":[{"name":"Edinburgh Breast Unit Research Group, Western General Hospital, Edinburgh EH4 2XU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Evans","sequence":"additional","affiliation":[{"name":"1Novartis Pharma AG, Femara GBTR-Research, Oncology, K136-P65, CH-4002 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Krause","sequence":"additional","affiliation":[{"name":"2Novartis Pharma AG, Biostatics, Clinical Modeling and Related Technologies, WSJ-27.1.076, CH-4002 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Dixon","sequence":"additional","affiliation":[{"name":"Edinburgh Breast Unit Research Group, Western General Hospital, Edinburgh EH4 2XU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070909173555300_ELLIS-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Ellis\n              MJ\n            \n          , Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M & Brady C 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2- positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology193808\u20133816.","DOI":"10.1200\/JCO.2001.19.18.3808"},{"key":"2026070909173555300_FORREST-ETAL-1986","doi-asserted-by":"crossref","unstructured":"Forrest\n              AP\n            \n          , Levack PA, Chetty U, Hawkins RA, Miller WR, Smyth JF & Anderson TJ 1986 A human tumour model. Lancet2840\u2013842.","DOI":"10.1016\/S0140-6736(86)92872-2"},{"key":"2026070909173555300_KEEN-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Keen\n              JC\n            \n          , Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C & Miller WR 1997 Expression of Ki- S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Research and Treatment44123\u2013134.","DOI":"10.1023\/A:1005796915388"},{"key":"2026070909173555300_MILLER-ETAL-1999","unstructured":"Miller\n              WR\n            \n          , Anderson TJ, Hawkins RA, Keen J & Dixon JM 1999 Neoadjuvant endocrine treatment: the Edinburgh experience. In Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, pp 89\u201399. Eds M Doswett & A Howell. Amsterdam: Elsevier."},{"key":"2026070909173555300_MILLER-AND-LARIONOV-2005","doi-asserted-by":"crossref","unstructured":"Miller\n              WR\n            \n           & Larionov A 2005 Aromatase 2004, Edinburgh, UK, 6\u20138 September 2004. Breast Cancer Research7E2.","DOI":"10.1186\/bcr964"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/12\/Supplement_1\/0120119.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/12\/Supplement_1\/S119\/192169\/0120119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/12\/Supplement_1\/S119\/192169\/0120119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:17:42Z","timestamp":1783603062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/12\/Supplement_1\/S119\/34471\/Growth-factor-signalling-in-clinical-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":5,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1677\/erc.1.00995","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}